05 January 2021
Despite the challenges posed by the COVID-19 pandemic, Medannex completed its planned expansion to 12 employees over the course of 2020.
With new in-house expertise in several key areas, including clinical project management and regulatory affairs, the company is well-positioned to initiate a First-in-Human clinical study later this year.
The company looks forward to generating the first clinical data on its lead antibody therapy, MDX-124, which has shown significant anti-cancer activity in multiple non-clinical models.